Novo Nordisk opens weight loss drug Wegovy to telehealth; Hims & Hers shares rocket 30%
Novo Nordisk is racing to capture more patients now that many compounding pharmacies are restricted from making Wegovy copycats, with rare exceptions.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
